0.01231  -0.005 (-27.59%)		04-09 09:30
Open: 0.0152 High: 0.0168 Volume: 3,056,446		Pre. Close: 0.017 Low: 0.0082 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.25	1-year :	0.4
Resists	First :	0.21	Second :	0.34
Pivot price	0.12
Supports	First :	0	Second :	0
MAs	MA(5) :	0.03	MA(20) :	0.14
	MA(100) :	0.45	MA(250) :	0.97
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	6.2	D(3) :	5.9
RSI	RSI(14): 21
52-week	High :	2.78	Low :	0

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IOBT ] has closed above bottom band by 12.4%. Bollinger Bands are 25.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.02 - 0.02	0.02 - 0.02
Low:	0.01 - 0.01	0.01 - 0.01
Close:	0.01 - 0.01	0.01 - 0.01

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Wed, 08 Apr 2026
IOBT Should I Buy - Intellectia AI

Mon, 06 Apr 2026
Why Is IO Biotech, Inc. (IOBT) Stock Down Today? - Meyka

Mon, 06 Apr 2026
HBM Healthcare (IOBT) reports 2.43M-share stake including warrants (3.3%) - Stock Titan

Sun, 05 Apr 2026
IO Biotech, Inc.(OTCPK: IOBT.Q) dropped from NASDAQ Composite Index - marketscreener.com

Wed, 01 Apr 2026
IOBT SEC Filings - Io Biotech, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Tue, 31 Mar 2026
IO Biotech (IOBT) shuts down and files for Chapter 7 liquidation - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	72 (M)
Shares Float	38 (M)
Held by Insiders	6.6 (%)
Held by Institutions	46.7 (%)
Shares Short	2,820 (K)
Shares Short P.Month	4,260 (K)

EPS	-1.35
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-88.6 %
Return on Equity (ttm)	-240.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.28
Qtrly Earnings Growth	0 %
Operating Cash Flow	-81 (M)
Levered Free Cash Flow	-49 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	1.23
Price to Sales	0
Price to Cash Flow	-0.02

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.